Skip to main content
SMO ClinPlus CO., LTD. logo

SMO ClinPlus CO., LTD. — Investor Relations & Filings

Ticker · 301257 ISIN · CNE100005CP8 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 483 across all filing types
Latest filing 2025-05-14 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 301257

About SMO ClinPlus CO., LTD.

https://www.smo-clinplus.com

SMO ClinPlus CO., LTD. is a professional Site Management Organization (SMO) providing comprehensive clinical trial site management services. The company specializes in supporting pharmaceutical, biotechnology, and medical device developers throughout the clinical development lifecycle. Core services include the provision of Clinical Research Coordinators (CRCs), site feasibility assessments, patient recruitment and retention strategies, and clinical trial data management. ClinPlus facilitates the execution of clinical trials by managing administrative and operational tasks at research sites, ensuring compliance with Good Clinical Practice (GCP) and regulatory requirements. With an extensive network of partner hospitals and research institutions, the company streamlines the clinical research process, enhances data quality, and accelerates project timelines for domestic and international sponsors.

Recent filings

Filing Released Lang Actions
关于部分首次公开发行前已发行股份上市流通提示性公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement regarding the lifting of trading restrictions on certain pre-IPO shares of the company 普蕊斯 (Shanghai) Medical Technology Development Co., Ltd. It includes information about the number of shares becoming tradable, shareholder commitments, stock structure changes, and regulatory compliance. The document is not a financial report, earnings release, or management discussion, but rather a regulatory announcement about share listing and circulation. It does not contain financial statements or earnings data. The content fits the category of a Regulatory Filing (RNS) as it is a compliance and disclosure announcement related to share circulation and shareholder commitments, typical for regulatory filings in the Chinese market. The document length (6553 characters) and detailed nature support this classification rather than a brief report publication announcement or other categories.
2025-05-14 Chinese
华泰联合证券有限责任公司关于普蕊斯（上海）医药科技开发股份有限公司部分首次公开发行前已发行股份上市流通的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from Huatai United Securities Co., Ltd. regarding the unlocking and listing circulation of certain pre-IPO shares of Puris (Shanghai) Pharmaceutical Technology Development Co., Ltd. It discusses the company's stock issuance, changes in share capital, shareholder commitments on share lock-up and reduction, and the schedule for lifting restrictions on shares. The document includes specific dates, share quantities, shareholder names, and compliance with regulatory requirements. It is not a financial report like an annual or interim report, nor is it a simple announcement. Instead, it is a regulatory compliance and verification report related to share lock-up release and listing circulation, which fits best under the category of Regulatory Filings (RNS) as it does not match other more specific categories such as Capital/Financing Update or Share Issue/Capital Change. The document is over 6,000 characters and contains substantive content, not just a brief announcement or certification. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2025-05-14 Chinese
关于召开2024年年度股东大会提示性公告
AGM Information Classification · 100% confidence The document is a detailed announcement about the convening of the 2024 Annual General Meeting (AGM) of 普蕊斯（上海）医药科技开发股份有限公司. It includes information about the meeting date, voting procedures, agenda items to be discussed and voted on, registration details, and attachments such as proxy forms and voting instructions. The document does not contain financial statements or detailed financial analysis but serves as a notice and guide for shareholders to participate in the AGM. Therefore, it fits the category of AGM Information (AGM-R). The document length and content confirm it is not a brief announcement but a full AGM notice with relevant materials.
2025-05-14 Chinese
关于获得政府补助的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (1100 characters) about the company receiving a government subsidy. It details the nature of the subsidy, accounting treatment, and its expected impact on profits. There are no financial statements or comprehensive financial data presented. The document is an official disclosure of a government grant received, which is a regulatory announcement rather than a full financial report or earnings release. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Capital/Financing Update. It is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about government subsidy receipt and its accounting treatment.
2025-04-29 Chinese
2024年度监事会工作报告
Management Reports Classification · 95% confidence The document is titled as the "2024年度监事会工作报告" (2024 Supervisory Board Work Report) of 普蕊斯（上海）医药科技开发股份有限公司. It details the supervisory board's activities, meetings, and oversight of the company's operations, financial status, internal controls, and compliance with laws and regulations during the 2024 fiscal year. The report includes detailed supervisory opinions on financial management, fundraising usage, related party transactions, internal controls, insider information management, and information disclosure. It also outlines the supervisory board's work plan for 2025. The document is a formal report from the supervisory board, which is a management oversight body, providing detailed management-related information and oversight results rather than a full annual report or audit report. It is not a simple announcement or certification but a substantive management oversight report. Therefore, the document fits best under the category of Management Reports (MDA), which covers management's detailed explanation of financial results, business trends, and outlook, including supervisory board reports.
2025-04-28 Chinese
独立董事刘学先生2024年度述职报告
Board/Management Information Classification · 95% confidence The document is a detailed annual performance report by an independent director of a company, describing their duties, attendance at board meetings, committee work, oversight of financial reports, and other governance activities during the year 2024. It includes references to compliance with laws and regulations, internal control evaluations, audit firm appointment, and shareholder rights protection. This type of document is a formal report on board/management activities and governance oversight rather than a financial report, earnings release, or regulatory filing. It does not contain financial statements or earnings data but focuses on the independent director's role and activities. Therefore, it fits best under the category of Board/Management Information (MANG). The document length and content confirm it is a full report, not a brief announcement or certification.
2025-04-28 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.